The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1
Hanks, S. K., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768349 · Cited by 2,318
The protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Brognard, J., Clark, A. S., Ni, Y., & Dennis, P. A. (2001) · PubMed · Cited by 987
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G., & Stokoe, D. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00493-9 · Cited by 477
Chapter 26. Privileged structures — An update
Patchett, A. A., & Nargund, R. P. (2000) · Annual Reports in Medicinal Chemistry · doi:10.1016/s0065-7743(00)35027-8 · Cited by 302
Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.
Page, C., Lin, H., Jin, Y. H., et al. (2000) · PubMed · Cited by 220
Novel PI Analogues Selectively Block Activation of the Pro-survival Serine/Threonine Kinase Akt
Kozikowski, A. P., Sun, H., Brognard, J., & Dennis, P. A. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0285159 · Cited by 198
Zinda, M. J., Johnson, M., Paul, J., Horn, C. L., Konicek, B. W., Lü, Z., Sandusky, G. E., Thomas, J. E., Neubauer, B. L., Lai, M. T., et al. (2001) · PubMed · Cited by 148
Cited by
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Akt signalling in health and disease
Hers, I., Vincent, E. E., & Tavaré, J. M. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.05.004 · Cited by 1,239
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
“AKTi-1/2 and AKTi-1/2/3 are PH-domain dependent, non-ATP-competitive inhibitors that potently inhibit AKT1 and AKT2, and not other AGC kinases, with AKTi-1/2/3 having greater potency against AKT3 (Barnett et al., 2005; Lindsley et al., 2005).”
InfluentialHirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860
AKT as a Therapeutic Target for Cancer
Song, M., Bode, A. M., Dong, Z., & Lee, M.-H. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2738 · Cited by 782
The impact of microwave synthesis on drug discovery
Kappe, C. O., & Dallinger, D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1926 · Cited by 610
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., & Workman, P. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.004 · Cited by 543
The Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
Self-citationDrug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
NITULESCU, G. M., MARGINA, D., JUZENAS, P., PENG, Q., OLARU, O. T., SALOUSTROS, E., FENGA, C., SPANDIDOS, D. A., LIBRA, M., & TSATSAKIS, A. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 364
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Chakrabarty, A., Sánchez, V., Kuba, M. G., Rinehart, C., & Arteaga, C. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018001108 · Cited by 347
PI3K/PTEN signaling in tumorigenesis and angiogenesis
Jiang, B.-H., & Liu, L.-Z. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.09.008 · Cited by 345
Synthetic applications of fluorous solid-phase extraction (F-SPE)
Zhang, W., & Curran, D. P. (2006) · Tetrahedron · doi:10.1016/j.tet.2006.08.051 · Cited by 344
Akt-regulated pathways in prostate cancer
Majumder, P. K., & Sellers, W. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209096 · Cited by 344
Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition
Wu, W.-I., Voegtli, W. C., Sturgis, H. L., Dizon, F. P., Vigers, G. P. A., & Brandhuber, B. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012913 · Cited by 331
Physiological roles of PKB/Akt isoforms in development and disease
Dummler, B., & Hemmings, B. A. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350231 · Cited by 316
Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma
Fan, Q.-W., Cheng, C., Hackett, C., Feldman, M., Houseman, B. T., Nicolaides, T., Haas-Kogan, D., James, C. D., Oakes, S. A., Debnath, J., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2001017 · Cited by 295
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Morphy, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901132v · Cited by 292
Amin, R. H., & Schlissel, M. S. (2008) · Nature Immunology · doi:10.1038/ni.1612 · Cited by 286
Drugs for Allosteric Sites on Receptors
Wenthur, C. J., Gentry, P. R., Mathews, T. P., & Lindsley, C. W. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134525 · Cited by 273
Self-citationCarnero, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941865 · Cited by 272
Targeting phospholipase D in cancer, infection and neurodegenerative disorders
Brown, H. A., Thomas, P. G., & Lindsley, C. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.252 · Cited by 209
Self-citationFang, Z., Grütter, C., & Rauh, D. (2013) · ACS Chemical Biology · doi:10.1021/cb300663j · Cited by 197
Targeting Protein-Protein Interaction by Small Molecules
Jin, L., Wang, W., & Fang, G. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140028 · Cited by 195
Protein kinase B activity is required for the effects of insulin on lipid metabolism in adipocytes
Berggreen, C., Gormand, A., Omar, B., Degerman, E., & Göransson, O. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90596.2008 · Cited by 118
Nox4 regulates InsP3 receptor‐dependent Ca2+ release into mitochondria to promote cell survival
Beretta, M., Santos, C. X., Molenaar, C., Hafstad, A. D., Miller, C. C., Revazian, A., Betteridge, K., Schröder, K., Streckfuß‐Bömeke, K., Doroshow, J. H., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103530 · Cited by 93
Endomembrane PtdIns(3,4,5)P3 activates the PI3K-Akt pathway
Jethwa, N., Chung, G. H. C., Lete, M. G., Alonso, A., Byrne, R. D., Calleja, V., & Larijani, B. (2015) · Journal of Cell Science · doi:10.1242/jcs.172775 · Cited by 68
ER Stress Induces Anabolic Resistance in Muscle Cells through PKB-Induced Blockade of mTORC1
Deldicque, L., Bertrand, L., Patton, A., Francaux, M., & Baar, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020993 · Cited by 50
“This phenotype is replicated by the PKB inhibitor Akti suggesting that basal PKB activity is required for amino acid induced activation of mTORC1.”
BackgroundInfluential
Metadata
- Authors
- Lindsley, C. W., Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., & Duggan, M. E.
- Venue
- Bioorganic & Medicinal Chemistry Letters
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 15
- Issue
- 3
- Pages
- 761-764
- ISSN
- 0960-894X (ISSN-L)
- OpenAlex
- W2177206102
- Cited by
- 503
- References
- 14
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.